No abstract

Aim: The number of comorbid diseases increased with the rise in the elderly population. In some cases, the state of deficient or absent nutrition emerges. Nevertheless, the contribution of percutaneous endoscopic gastrostomy (PEG) to the quality of life and the survival rate in the elderly with certain diseases remains controversial. Methods: In this prospective cohort study, patients who underwent percutaneous endoscopic gastrostomy (PEG) procedure between 2009 and 2015 were divided into two groups: CVE group consisted of patients with cerebrovascular event (CVE) and non-CVE group comprised patients who suffered from esophageal tumors, head and neck tumors, brain tumors, amyotrophic lateral sclerosis and terminal dementia. In this study, the patients' pre-PEG and post-PEG body mass index (BMI) values, hemoglobin (Hb), albumin (alb), creatinine (Cr) and C-reactive protein (CRP) values, white blood cell counts, demographic characteristics, 30, 90, 180 and 365 daysurvival rates, complications (mechanical, metabolic and infectious) and duration of patency of the PEGs were compared. Results: The average age was lower while survival rate on the 90 th day was higher in the CVE group. No significant difference was found in terms of other parameters. At the end of the one-year follow-up, 21% of the patients in the CVE group and 12% of those in the non-CVE group were able to be fed without PEG. Conclusion: PEG patency was higher in the CVE group at 3 months but there was no statistically significant difference between the groups at one-year and overall follow-up periods.

Background/Aim: Non-alcoholic fatty liver is quite common among modern populations, and simpler methods are researched for its early diagnosis and therapy. Studies are stating that vitamin D deficiency could play a role in the etiopathogenesis of fatty liver. This study aimed to compare the efficacy of metformin and vitamin D therapy in improving fatty liver disease. Methods: A total of 86 patients with non-alcoholic fatty liver disease were included in this case control study and classified into four groups according to the treatment received. In the study group, 23 patients were using metformin only, and 21 patients were using both metformin and vitamin D. Twenty-one patients were using vitamin D only, and 21 patients were on a diet and an exercise regimen (control group). Weight, BMI, waist circumference, fatty liver index (FLI), HOMA-IR, AST, ALT, GGT, triglyceride parameters were evaluated before and after four weeks of therapy. Results: There was a significant regression in the fatty liver disease of the patients who used both metformin and vitamin D (FLI-%5, 90 (11.1) P=0.025). Among patients who used only metformin and only vitamin D, the decrease in FLI was not significant (P>0.05); however, FLI was observed to significantly decrease in the control group (-7.30, P=0.018). The serum CRP levels were also observed to significantly decrease in the control, Met and Met-D vit groups (P=0.025, P=0.002, P=0.006, respectively). Conclusions: The combination of vitamin D and metformin therapy could positively contribute to the improvement of NAFLD in patients with vitamin D deficiency.